Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I).
LT-IIb, a type II heat-labile enterotoxin of Escherichia coli, is a potent immunologic adjuvant with high affinity binding for ganglioside GD1a. Earlier study suggested that LT-IIb bound preferentially to the terminal sugar sequence NeuAcalpha2-3Galbeta1-3GalNAc. However, studies in our laboratory suggested a less restrictive binding epitope. LT-IIb(T13I), an LT-IIb variant, engineered by a single isoleucine-threonine substitution, retains biological activity, but with less robust inflammatory effects. We theorized that LT-IIb has a less restrictive binding epitope than previously proposed and that immunologic differences between LT-IIb and LT-IIb (T13I) correlate with subtle ganglioside binding differences. Ganglioside binding epitopes, determined by affinity overlay immunoblotting and enzymatic degradation of ganglioside components of RAW264.7 macrophages, indicated that LT-IIb bound to a broader array of gangliosides than previously recognized. Each possessed NeuAcalpha2-3Galbeta1-3GalNAc, although not necessarily as a terminal sequence. Rather, each had a requisite terminal or penultimate single sialic acid and binding was independent of ceramide composition. RAW264.7 enterotoxin-binding and non-binding ganglioside epitopes were definitively identified as GD1a and GM1a, respectively, by enzymatic degradation and mass spectroscopy. Affinity overlay immunoblots, constructed to the diverse array of known ganglioside structures of murine peritoneal macrophages, established that LT-IIb bound NeuAc- and NeuGc-gangliosides with nearly equal affinity. However, LT-IIb(T13I) exhibited enhanced affinity for NeuGc-gangliosides and more restrictive binding. These studies further elucidate the binding epitope for LT-IIb and suggest that the diminished inflammatory activity of LT-IIb(T13I) is mediated by a subtle shift in ganglioside binding. These studies underscore the high degree of specificity required for ganglioside-protein interactions.
Berenson
Charles S
CS
Infectious Disease Division, Department of Veterans Affairs Western New York Healthcare System, State University of New York at Buffalo School of Medicine, Buffalo, NY 14215, USA. berenson@buffalo.edu
Nawar
Hesham F
HF
Yohe
Herbert C
HC
Castle
Sherry A
SA
Ashline
David J
DJ
Reinhold
Vernon N
VN
Hajishengallis
George
G
Connell
Terry D
TD
D000818:Animals; D001427:Bacterial Toxins / Q000737:chemistry*; D002460:Cell Line; D002518:Ceramides / Q000737:chemistry; D003016:Clostridium perfringens / Q000201:enzymology; D004768:Enterotoxins / Q000737:chemistry*; D000939:Epitopes / Q000737:chemistry; D004926:Escherichia coli / Q000378:metabolism*; D029968:Escherichia coli Proteins / Q000737:chemistry*; D005732:Gangliosides / Q000737:chemistry*; D006028:Glycosphingolipids / Q000737:chemistry; D007249:Inflammation; D008264:Macrophages / Q000166:cytology; D013058:Mass Spectrometry / Q000379:methods; D051379:Mice; D019158:N-Acetylneuraminic Acid / Q000737:chemistry; D011485:Protein Binding
D001427:Bacterial Toxins; D002518:Ceramides; D004768:Enterotoxins; D000939:Epitopes; D029968:Escherichia coli Proteins; D005732:Gangliosides; D006028:Glycosphingolipids; C027538:heat-labile enterotoxin, E coli; D019158:N-Acetylneuraminic Acid